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Abstract: Local anesthetics block the transmission of painful stimuli to the brain by acting on 
ion channels of nociceptor fibers, and find application in the management of acute and chronic 
pain. Despite the key role they play in modern medicine, their cardio and neurotoxicity (together 
with their short half-life) stress the need for developing implantable devices for tailored local drug 
release, with the aim of counterbalancing their side effects and prolonging their pharmacological 
activity. This review discusses the evolution of the physical forms of local anesthetic delivery 
systems during the past decades. Depending on the use of different biocompatible materials 
(degradable polyesters, thermosensitive hydrogels, and liposomes and hydrogels from natural 
polymers) and manufacturing processes, these systems can be classified as films or micro- or 
nanostructured devices. We analyze and summarize the production techniques according to this 
classification, focusing on their relative advantages and disadvantages. The most relevant trend 
reported in this work highlights the effort of moving from microstructured to nanostructured 
systems, with the aim of reaching a scale comparable to the biological environment. Improved 
intracellular penetration compared to microstructured systems, indeed, provides specific drug 
absorption into the targeted tissue and can lead to an enhancement of its bioavailability and 
retention time. Nanostructured systems are realized by the modification of existing manufacturing 
processes (interfacial deposition and nanoprecipitation for degradable polyester particles and 
high- or low-temperature homogenization for liposomes) or development of novel strategies 
(electrospun matrices and nanogels). The high surface-to-volume ratio that characterizes nano-
structured devices often leads to a burst drug release. This drawback needs to be addressed to 
fully exploit the advantage of the interaction between the target tissues and the drug: possible 
strategies could involve specific binding between the drug and the material chosen for the device, 
and a multiscale approach to reach a tailored, prolonged drug release.
Keywords: pain management, microparticle, microencapsulation, nanoparticle production, 
nanogels, liposomes
Local anesthetics: clinical relevance for their use 
in implantable delivery systems
Local anesthetics (LAs) temporarily and reversibly prevent nociceptive nervous fibers 
from sending stimuli to the brain.1 These drugs act by blocking sodium and other ion 
channels present in the nerve cell membrane, thereby stopping the electrical signal 
before it can cause feelings of pain.1,2
LAs have been used for acute or chronic pain management, and their principal use 
is after surgery (eg, thoracotomy, laparotomy, cesarean section, breast cancer surgery, 
cosmetic breast surgery, limb amputation, and others).2,3 A recent study has highlighted 
the importance of LA administration after major operations to ward off chronic pain 
onset after thoracotomies and cesarian sections.3
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As nociceptive inputs from the wound play a major role, 
it is logical to “go back to the periphery”, acting locally, to 
prevent nociceptive inputs from reaching the central nervous 
system and triggering endogenous pain processes.4 Peripheral 
LA administration is a rational approach to control pain.5 
Continuous wound infusion (CWI) prolongs the action of 
LAs, thus improving their efficacy. Experimental models 
of incisional pain6 have demonstrated that the CWI of LAs 
modulates peripheral inflammation and sensitization in acute 
post-operative pain (PP). CWI is effective in controlling pain 
and reducing postoperative morphine administration after a 
major surgery.7 CWI through an intralesional catheter presents 
several limitations such as risk of infection (external device), 
reduction in patient activity (compliance patient problems), 
difficulty in administration (need to fill the device many 
times), and systemic toxicity related to inaccurate adminis-
tration of LAs or steroids, such as convulsions, arrhythmias, 
cardiovascular (hypo- or hypertension) and metabolic (eg, 
hyperglycemia) problems.
Clinically used LAs possess common chemical structural 
characteristics, in which three chemical moieties can be 
identified: a hydrophilic amino group, a lipophilic benzene 
ring, and an intermediate chain8 (Figure 1). The intermediate 
chain can be an amide or an ester group, which allows clas-
sifying the drug as an ester-type or amide-type LA.8 Some 
of the most used amide types are lidocaine, bupivacaine, 
dibucaine, mepivacaine, and ropivacaine, whereas the most 
common ester types are benzocaine, tetracaine, proparacaine, 
procaine, and chloroprocaine. Some molecules present iso-
merism: the most diffuse chiral molecules are bupivacaine 
and prilocaine,1,8 with the (S)-enantiomer being more active 
and less toxic than the (R)-form.9
The duration of a drug’s effect is related to its protein-binding 
ability. Agents that penetrate the nerve membrane and attach 
more firmly to the membrane proteins show prolonged activity, 
eg, tetracaine, bupivacaine, and etidocaine. On the contrary, pro-
caine binds poorly to proteins and possesses a short half-life.10 
LAs bind also to plasma proteins, albumin (low affinity), and 
α-1-acid glycoprotein (high affinity), leading to the same effects 
as tissue proteins.11 The duration of drug’s action is also related 
to its structure, length, and the groups present.
Amide type is generally more stable and possesses a 
long er half-life than ester type, which undergoes rapid 
hydrolysis by nonspecific esterases.11
Most of the clinically useful LAs are available in two 
forms: as free base or as a salt. The salt form has greater 
solubility in aqueous media and thus is preferred for a drug 
delivery system.10,12 The salt, being a weak base, can exist in 
solution as an un-ionized free base, which is more lipophilic, 
or as a positively charged cation; both species are involved in 
the process of conduction blocking.10,13 The base crosses the 
neuronal bilayer more easily, and thus is preferred for opti-
mal penetration.10 The percentage of drug in the two forms 
depends on its pK
a
 and the environmental pH. Each drug has 
a characteristic pK
a
, with ester type LAs typically having a 
higher value than the amide type.11 The closer the pK
a
 is to 
the pH of the tissues, the faster is the onset of action of the 
drug,13,14 since the percentage of free base formed increases. 
For this reason, in infected tissues, the LA effect is reduced 
or even delayed, as the environment tends to be more acidic 
than usual and the un-ionized form decreases.10
Even though anesthesiologists often prefer them to gen-
eral anesthetics, LAs present side effects like allergies1,2,8 
and stroke15,16 related to their chemical structure (eg, ester 
types are more problematic than amide types). In particular, 
lidocaine and bupivacaine have caused strokes leading to 
death of the patient.15
Chloroprocaine, an ester type LA, has been demonstrated 
to be less cardiotoxic than most other LAs,15 but it has an 
extremely short half-life: ,10 minutes in vivo.17
Recently, drug delivery systems, according to different 
user needs obtained by a variety of materials and physical 
forms, have been developed to minimize severe side effects 
and to prolong the anesthetic action.1
The state of art: local anesthetic 
delivery
Implantable systems used for LA delivery
Injectable and implantable systems for LA delivery aim to 
reduce LA toxicity and prolong the anesthetic effect of drugs 
with short half-lives, shielding the drug from the environment 
of the implantation site.1
New delivery platforms are necessary to obtain effec-
tive, lasting postoperative peripheral analgesic treatment for 
5
1
5′
Figure 1 Typical structure of a local anesthetic: amino group (orange), benzene ring 
(red), intermediate carbon chain (blue).
Notes: The presence of an amide or ester group in the intermediate chain leads to 
the classification of the drug as ester-type or amide-type local anesthetic. R and R′ 
represent two different chemical groups.
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several days to block the nociceptive message and to reduce 
postoperative inflammatory response. This platform has to 
overcome the limitations of the external inaccurate delivery 
devices. The development of intraoperative nanogel delivery 
systems, able to provide anesthetics with planned dosages and 
timing, is a key step toward attaining the safest and most effec-
tive postoperative treatment. Nanotechnology plays a critical 
role in the development of patient-specific therapies and indi-
vidualized medicine and offers great opportunities for combat-
ing the limitations of postoperative pain management.
One of the simplest systems for LA delivery is rep-
resented by the oil depot formulation: lipophilic drugs 
(eg, lidocaine,18–20 bupivacaine,21 or ropivacaine21,22) are 
dissolved in different biocompatible oils18–22 and injected 
intramuscularly, subcutaneously, or intra-articularly.
In esthetic medicine, lidocaine loaded-commercial fillers 
are commonly employed in patients. For these applications, 
the release profile is not studied because its characterization 
is not an intended scope, as they are not designed as drug 
delivery systems, with LAs added to reduce pain during the 
filler injection.
Calcium phosphates were loaded with lidocaine for 
bone defect reconstruction to provide relief from pain after 
implant.23,24 Scaffolds were formed by sintering ceramic 
powers and infiltrating them with lidocaine solutions 
(60 mg/mL23 and 20 mg/mL24). To treat pain after tooth 
extraction, other implantable devices were developed to 
fill the bone gap, mixing commercial bone putty (Xybrex; 
Orthocon, Inc., Irvington, NY, USA) and lidocaine25 or devel-
oping sponge-like polycationic and polyanionic hydrogel 
fillers: lidocaine solution (up to 4 mg/mL) was incorporated 
into polymer solutions before cross-linking.26
However, none of these systems for LA delivery was 
developed for a prolonged, tailored release.
Application of micro/nanodevices in the 
clinical practice
Current achievements and future perspectives in pain therapy 
raise the question whether hospitalization without pain is 
still wishful thinking or can became a reality. Micro and 
then nanodevices are on the horizon of new technologies 
for pain management, which can overcome the limitations 
of traditional anesthetic delivery tools, such as drug delivery 
security and safety of the delivery system, simplicity of set-
ting up, as well as maintenance and management. These sys-
tems consist in micro- and nanostructured films, particles, 
capsules (suspended in a solution or embedded in a gel 
matrix), and hydrogels, which can be implanted in the site of 
surgery and release LAs in a tailored manner. Irrespective of 
the origin of pain, management is necessary in clinical prac-
tice leading to essential benefits including shorter hospital 
stay and improved patient satisfaction. Otherwise, totally 
implantable devices (according to the US Food and Drug 
Administration [FDA], ISO 10993-1 micro/nanodevices must 
be categorized as implant devices with prolonged exposure 
to the body) with their full integration with the biological 
milieu of the human body is still a crucial multidisciplinary 
task to solve. From a clinical perspective, the ideal pain 
management should cover the entire period necessary with 
as little discomfort as possible to the patient. The produc-
tion of devices as biocompatible and small as possible 
can prevent discomfort. This concept drives this clinically 
translational research to manufacturing a device character-
ized by features from micro to nano if considering physical 
size as the major overriding issue (even if not the only one). 
LAs, as the main actors of drug delivery through implanted 
nanodevices, play a pivotal role for the entire system due to 
their peculiar characteristics: completely reversible action 
and the relative absence of collateral or side effects compared 
to other drugs generally used in the clinical scenario. Their 
use is nowadays limited to intravenous patient-controlled 
analgesia or patient-controlled epidural systems. Although 
these analgesic methods are commonly used, they are not free 
from important disadvantages including their invasiveness 
and the need for pumping equipment, tubes, or power lines, 
which could potentially limit patient mobility during, for 
example, the postoperative period. They also require exhaus-
tive staff-time preparation and resources with the risk of 
catheter dislodgement or epidural hematoma (increased in 
case of coadministration of anticoagulant therapy). These 
limitations show why the development of LA drug delivery 
system administering therapy from inside the patient’s own 
body is so crucial and, secondly, why nanotechnology has 
received a never-seen-before enthusiasm in this field.
Toward tailored, controlled LA 
delivery with implantable and 
injectable systems
Drug delivery systems described so far are the widest and 
simplest methods for LA administration. Among them, it 
is possible to find also commercial products (eg, EMLA 
cream27). More advanced ones have been developed to treat 
the urgent issues represented by chronic and postoperative 
pains. These can be classified as films, or micro- or nano-
structured systems, depending on the final shape and size of 
the devices constituted by different materials and realized 
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using different techniques (Figure 2). A summary of all 
the reviewed systems, based on the employed materials, is 
described in Tables 1–4.
Films
Drug delivery systems in form of films were developed in par-
ticular for wound treatment or as transdermal patch.28 Implant-
able films were produced by UV polymerization29,30 or solvent 
casting.31–33 The UV curing technique consists of cross-linking 
polymer chains using UV radiation and loading the drug29 
prior to the cross-linking. Depending on the type of materi-
als, the loading can vary from 10 µg/g of film in the case of a 
semi-interpenetrated network obtained through UV-curing of 
poly(ethylene glycol) (PEG) diacrylate in presence of gelatin30 
to ~25 mg of drug/g of film using N-isopropylacrylamide 
(NIPAAm) and 1-vinyl-2-pyrrolidinone.29 Thermoresponsive 
polymer chains can lead to a more compact hydrogel network, 
slowing down the drug release.
/HQJWKVFDOH
0LOOL
0LFUR
1DQR
/LSRVRPHV
3RO\PHUV
6ROLGOLSLGQDQRSDUWLFOHV1DQRILEHUV1DQRJHOV
)LOP
&DSVXOHV
7KHUDSHXWLFDJHQW
6SKHUHV3DUWLFOHV
Figure 2 Local anesthetic delivery systems can be produced at different length scales (milli, micro, or nano) using different physical forms: films, capsules, spheres and 
particles, liposomes, nanofibers, and nanogels.
Table 1 Summary of polyester-based local anesthetic delivery systems
Material Physical form Production process Local anesthetic
PLA32,33,35–39,42,43,48,51,53,54,90,91,94,95,101
PLGA34,35,40,41,45–47,49,50,52,54,92,95–103
PCL51,93,101
Film32,33 Solvent casting32,33 Lidocaine32
Bupivacaine33
Microparticle32
Microcapsule48,51
Drug/polymer solution
Spray-dryer45–47 Bupivacaine45–47
Flow-focused method49–51 Lidocaine49,51
Bupivacaine50
O/w emulsion
Solvent evaporation32,34–42 Lidocaine32,34,37–39,41,42
Bupivacaine35,36,40,41
Double emulsion (water/oil/water) + solvent 
evaporation42,43,52
Lidocaine42,52
Prilocaine43
Spray-drying48 Procaine48
Flow-focused method51 Lidocaine51
In situ forming particles53,54 Bupivacaine53,54
Tetracaine54
Nanoparticle90–99
Nanocapsule100–102
Nanostructured matrix103
O/w emulsion90–93 Procaine94–96
Lidocaine90,91,93
Ropivacaine92
Benzocaine100–102
Bupivacaine97–99,103
Nanoprecipitation94–99
Interfacial deposition100–102
electrospinning103
Abbreviations: PLA, poly(lactic acid); PLGA, poly(lactic-co-glycolic acid); PCL, poly(ε-caprolactone); O/w, oil/water.
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Solvent casting technique can be applied by exploiting 
different strategies for drug loading, either during or after 
the solvent casting. Alternatively, drug loading was achieved 
by swelling a dried k-carrageenan film in dibucaine solu-
tion.31 Simultaneous film casting and drug encapsulation 
were achieved by loading lidocaine, a lipophilic drug, in a 
poly(lactic acid) (PLA) solution in chloroform.32 PLA was 
also employed to produce a composite film.33 During in vivo 
test in rats, drug release in the plasma lasted up to 10 days.
Although different materials and types of drug were used, 
when the drug was loaded in the step after film formation,31 
the release was faster than when the drug was loaded during 
the film preparation.32 Drug incorporation in the polymer 
solution can allow a homogeneous dispersion within the bulk 
of the material, but it is limited by the solubility of the drug 
in the solvent used for casting the film.
Microstructured systems
Microspheres, microparticles, and microcapsules are clas-
sified as microstructured systems, which can be implanted 
or injected once suspended in appropriate media, used as 
injectable matrices, or formed in situ (Figure 3). Among the 
several proposed solutions, the most widely used materials 
for microparticle production are synthetic degradable 
polyesters such as PLA, poly(glycolic acid), poly(lactic-co-
glycolic acid) (PLGA), and poly(ε-caprolactone).
The use of these materials to produce microspheres is 
related to the relative simplicity of microsphere production. In 
most of the works, microparticles were produced by oil/water 
(O/W)32,34–42 or water/oil/water (W/O/W) emulsions42,43 and 
solvent evaporation techniques. Usually, particles produced 
using those methods are solid and smooth microspheres, with 
a prolonged drug release lasting from 12 hours to 3–4 days. 
In some cases, dexamethasone was used as the excipient, 
enhancing bupivacaine’s in vivo effectiveness without 
modifying significantly the in vitro release profile.35,36,44
Alternatively, microspheres were produced through a 
spray-drying technique, which consists of spray-drying an 
organic drug/polymer solution.45–47 This technique requires 
higher and thus more expensive technology, but the cost of 
the spray-dryer is compensated by better results in terms of 
simplicity of the production process, narrower particle size 
distribution, and higher drug encapsulation efficiency.45 
Spray-drying can be exploited also to produce porous 
Table 2 Summary of hydrogel-based LA delivery systems
Material Physical form Production process Local anesthetic
T-responsive (NIPAAm29)
Gelatin-based30
k-carrageenan31
Film Uv polymerization29,30 Procaine29
Bupivacaine30
Solvent casting31 Dibucaine31
T-responsive (PNIPAAm56–58)
Chitosan-based62,63
PNIPAAm + chitosan59–61
Microparticle56–63 In situ
Injectable emulsion56–58 Lidocaine56–58
Injectable hydrogel62,63 Lidocaine62
Ropivacaine63
Injectable emulsion + matrix59–61 Bupivacaine59–61
pH-responsive polymers105–107
T-responsive polymers108,109
Liquid crystals110
Natural polymer based111
Nanoparticle105–111 emulsion polymerization105,106,108,109,111 Procaine105,106
Bupivacaine108,109,111
emulsion polymerization + layer-by-layer technique107 Procaine107
Self-assembly110 Bupivacaine110
Abbreviations: LA, local anesthetic; NIPAAm, N-isopropylacrylamide; PNIPAAm, poly(N-isopropylacrylamide); Uv, ultraviolet.
Table 3 Summary of phospholipid-based LA delivery systems
Physical form Production process Local anesthetic
Liposomes (LMv) + polymer coating77 Aqueous suspension of phospholipid films + solvent casting (natural polymers)77 Bupivacaine77
Liposomes: small unilamellar vesicles78–82
Lipid–protein–sugar particles55,85,86
Solid lipid nanoparticles87–89
LMv
Freeze-drying78,79 Lidocaine78
Bupivacaine79
extrusion81,82 Proparacaine81
Ropivacaine82
Homogenization80 Bupivacaine80
Spray-drying55,85,86 Bupivacaine55,85,86
High-pressure homogenization (no organic solvents)87–89 Tetracaine87,88
Bupivacaine89
Abbreviations: LA, local anesthetic; LMv, large multilamellar vesicle.
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Table 4 Summary of inorganic-powder-based LA delivery systems
Material Physical form Production process Local anesthetic
Calcium  
phosphates67,68
Microparticles67,68 wet granulation67 Drug = powder Lidocaine67
Isostatic compression67
wet impregnation68 Drug = solution Bupivacaine68
Silver104 Nanoparticles104 wet impregnation104 Procaine104
Dibucaine104
Tetracaine104
Abbreviation: LA, local anesthetic.
6SUD\GU\HU
)ORZIRFXVHGPHWKRG
(YDSRUDWLRQ
3RVVLELOLW\RIDGGLQJ3(*RUQDWXUDOSRO\PHUVIRUELRFRPSDWLELOLW\
2LOZDWHUHPXOVLRQ
2LOZDWHUHPXOVLRQ
6RQLFDWLRQ
39$VROXWLRQ
0RQRGLVSHUVHVROLGPLFURVSKHUHV
6ROLGVPRRWKPLFURVSKHUHV
,QVLWXIRUPLQJPLFURSDUWLFOHV
0RQRGLVSHUVHVROLGIURPVROXWLRQRUSRURXVIURPHPXOVLRQPLFURVSKHUHV
:DWHURLOZDWHUHPXOVLRQ
'RXEOHV\ULQJHPL[LQJ
'RXEOHHPXOVLRQ
5HVXOW
5HVXOW
5HVXOW
5HVXOW
$TXHRXVVROXWLRQ
3RO\PHUGUXJVRO
3RO\PHUGUXJVROLQRUJDQLFVROYHQW
'LUHFWO\WR
(PXOVLILHG
Figure 3 Scheme of production of microstructure systems.
Notes: Different techniques were developed depending on the materials used. Manufacturing processes starting from traditional synthetic polyesters begin from a solution 
of the polymer and drug or from an oil/water suspension of such a solution. Then they are processed through different methods (spray-drying, flow-focused method, 
evaporation, sonication, double-syringe mixing, and a second emulsion) to obtain microspheres.
Abbreviations: PeG, polyethylene glycol; sol, solution; PvA, polyvinyl alcohol.
microparticles by using an O/W emulsion instead of a drug–
polymer solution.
Porous microparticles were subsequently immersed in 
an aqueous solution of procaine (hydrophilic drug) and the 
particle pores were closed by adding an organic solvent in the 
procaine-loaded bath: in this way a hollow microcapsule was 
formed. This unconventional method succeeded in reaching 
drug release up to 9 days and to produce microcapsules that 
were more easily degradable.48
Another technique to produce monodisperse polymeric 
microspheres is flow-focusing.49–51 This technique employs 
a microfluidic device consisting of coaxial capillaries. At 
the inlet of the capillary with the larger diameter, the drug 
(lidocaine49,51 or bupivacaine50) and polymer organic solu-
tion follows in a certain direction, surrounded by polyvinyl 
alcohol (PVA) aqueous solution flowing in the same49,50 
or opposite direction.51 By tuning the process parameters 
(eg, viscosity of lipophilic and hydrophilic solutions), it is 
possible to produce microspheres with final characteristics 
close to the desired ones and with very narrow particle size 
distribution.49 Monodisperse microspheres showed slower 
drug release with reduced initial burst release compared 
to microspheres produced by traditional methods present-
ing similar average size but a broader size distribution.50 
Moreover, if O/W or W/O/W emulsions were used instead 
of a drug-loaded polymer solution, it is possible to obtain 
porous microparticles. This approach was followed by 
Vladisavljević et al,51 who used numerical simulation to 
find the most suitable process parameters (eg, flow rate and 
solution viscosities) to tailor particle characteristics.
Porous microparticles could be produced also using a 
simpler W/O/W technique. In contrast to the previously 
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described technique, the first emulsion consisted of a water-
in-oil emulsion in which the oily phase was constituted by 
PLGA dissolved in chloromethane in presence of lidocaine, 
which was subsequently mixed with an aqueous solution 
of PVA.52
In situ formation of microparticles was achieved by an 
emulsion of bupivacaine-loaded polymer (PLA with an 
emulsion stabilizer53 or PLGA54) solution in 2-pyrrolidone 
with an oily phase:53,54 emulsions were formed both by 
sonication and by manually mixing the contents of two 
syringes (one containing the oily phase and the other the 
polymer phase) previously connected with a double-female 
luer lock connector.
In spite of prolonged LA release by synthetic polyesters 
(up to 15–20 days32,47,49), they could also cause significant 
inflammatory reaction.55 For this reason, alternative strate-
gies were proposed.
In some studies, PLA or PLGA microsphere were pro-
duced in presence of PEG,37,42 which is well known for its 
nonfouling properties and can reduce inflammatory response. 
In one case, a mixture of the PLA and PEG was prepared, 
producing the microsphere by coacervation method, in which 
hexane (not able to dissolve PLA) was added to a stirred 
polymer solution (PLA + PEG + lidocaine) in methylene 
chloride. The coacervation droplets adhered to the suspended 
drug particles and coalesced around them to form polymer 
microparticulates.42
In another study, PLA/PEG copolymer was used and par-
ticles were realized following the O/W emulsion technique. 
In this case, particles were coated with gelatin by solvent-
casting of a gelatin solution to tailor the drug release, which 
reached 3-day release during in vitro tests in water at 37°C.37 
Combination with natural polymers is a strategy also used in 
another study, where PLGA microparticles were produced 
by an O/W emulsion in which alginate was dissolved in the 
aqueous solution.40 In vitro release of bupivacaine in PBS 
(37°C, pH 7.4) lasted for up to 24 hours.40
Other studies focused their attention on the use of stimuli-
responsive materials (Figure 4). Thermosensitive polymers 
such as poly(N-isopropylacrylamide) (PNIPAAm)56 and 
copolymers57,58 were used to produce microspheres by cross-
linking preformed polymer chains: an aqueous polymer 
solution was acidified and glutaraldehyde was added as the 
cross-linking agent. The solution was then poured into light 
mineral oil containing lecithin as emulsifying agent. Drug 
loading was obtained by soaking the microspheres in a 
lidocaine solution. However, this method did not guarantee 
prolonged drug release in PBS even up to 100 minutes 
in vitro.57 PNIPAAm microparticles were also embedded 
in an injectable chitosan thermogel matrix:59–61 the embed-
ding of microparticles was achieved through an innovative 
coinjection technique through a double-barreled syringe. 
In these cases, the chitosan matrix was useful to both pro-
longing bupivacaine release in PBS (.6 hours in vitro) and 
avoiding particle dispersion.59–61 Chitosan injectable loaded 
matrices62,63 were also studied with different results in terms 
of duration of anesthetic release in PBS: from 40 minutes62 
up to 48 hours.63 Other polymeric materials used for loaded 
microsphere production were tetraethoxysilane64,65 and 
poly(acrylic acid).66
Inorganic microparticulates can be loaded with LAs 
(Figure 5). Different methods of loading lidocaine on calcium 
phosphate powders were tested: wet granulation, isostatic 
compression, and a combination of both.67,68 These techniques 
&URVVOLQNLQJDQGDFLGLI\LQJDJHQWV
,VWHS
,,VWHS
5HVXOW
5HVXOW
3DUWLFOHVXVSHQVLRQ
0LFURVSKHUHVVRDNHGLQGUXJVROXWLRQ
0LFURVSKHUHVHPEHGGHGLQSRO\PHUPDWUL[
3RO\PHUVROXWLRQ'UXJ 
/LJKWPLQHUDORLO
&KLWRVDQWKHUPRJHO
Figure 4 Fabrication process from thermoresponsive materials starts from a polymer–drug solution poured into light mineral oil to create a suspension of microspheres that 
can be mixed with another thermogel matrix to embed them in it.
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started with mechanically mixing calcium phosphate and 
lidocaine. In wet granulation, the powder was moistened 
with water and passed through a sieve. Isostatic granula-
tion involves the application of high pressure to the mixed 
powder (calcium phosphate and lidocaine).67 Bupivacaine 
was loaded on calcium phosphate apatite: in this case, wet 
impregnation of an ethanol solution of the drug resulted in 
a uniform loading than when mixing bupivacaine powder 
with calcium phosphate powder.68
From micro to nano
In the past decades, a large number of publications have 
focused on the advantages resulting from the adoption of 
nanosystems instead of microsystems and therefore adopting 
different strategies to obtain nanoscale devices (Figure 6).
The aim of the scaling down is to make the size of the drug 
delivery system more similar to the biological environment, 
which is nanostructured. In this way, the molecular interac-
tions could be more specific, and the drug could be absorbed 
into the targeted tissue to attain an enhancement of its bio-
availability and retention time. The nanosystems, indeed, 
were demonstrated to improve intracellular penetration.69–71
In order to have a controlled and reliable LA release, 
the drug would be encapsulated in a biocompatible and 
biodegradable nanostructured system, to minimize tissue 
reaction and to control precisely the rate of drug delivery, 
which has to be comparable with the rate of generation of 
nontoxic de gradation products. In fact, an initial uncontrolled 
large dose of drug release could be lethal for the organ-
ism and therefore must be avoided.14,72 Moreover, LA 
nanoencapsulation increases the drug’s efficacy, specificity, 
tolerability, and therapeutic index.69
The LA release kinetics and the drug loading efficiency 
are influenced by the size of the system. Larger particles 
could load a larger amount of drug, leading to a longer block 
duration and thus a longer effect. On the contrary, smaller 
particles have the advantage of reducing the release rate of 
the incorporated drug, thereby improving the drug binding, 
even though smaller systems show a rapid initial release of 
the drug, which could be toxic.73 This is due to the fact that 
on moving from micro to nanosystems the surface-to-volume 
ratio of the particles increases and therefore also the initial 
dissolution rate.74,75 Therefore, the development of a nano-
structured system has to take into account ad hoc strategies to 
exploit the possible advantages offered by those systems (in 
particular the higher encapsulation efficiency and specificity 
in targeting biological structures) and limit the drawbacks 
related to their size.
Liposomes to solid lipid nanoparticles
Liposomes are phospholipid-based carriers.27 Because 
of their multilayered structure, with alternating aqueous 
compartment and lipid bilayer, they are able to incorporate 
both lipophilic and hydrophilic drugs, which can pass the 
lipophilic barrier of cell membranes.
The potential benefits in the use of liposomes as injectable 
or implantable devices for LA delivery were highlighted when 
it was found that an injection of soybean phosphatidylcholine 
nanoemulsion reduced bupivacaine’s cardiotoxicity.76
Liposome synthesis consists in obtaining large multila-
mellar vesicles (LMVs) from dried phospholipid films by 
suspending the film in an aqueous solution and vortexing it. 
Though LMVs were initially used, in also small unilamellar 
vesicles (SUVs) were also used.77 From an LMV suspension in 
5HVXOW
5HVXOW
,QFRQWDFWZLWKGUXJSRZGHUPHFKDQLFDOPL[LQJ
,QFRQWDFWZLWKGUXJVROXWLRQ
3RZGHURIFDOFLXPSKRVSKDWHV
'UXJVROXWLRQ
+RPRJHQHRXVORDGLQJRIWKHSRZGHU
'UXJQRQXQLIRUPORDGLQJRIWKHSRZGHU
'UXJVLHYLQJ ([WUXVLRQWKURXJKFRPSUHVVLRQ
'UXJORDGLQJ
&DOFLXPSKRVSKDWHV
Figure 5 Processes exploiting the use of calcium phosphates involve mechanical mixing or contact between the powder and contact between the powder and drug solution, 
which leads to a homogeneous drug loading different from the mechanical mixing.
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  
7HFKQLTXHVPDWHULDOVLQWULQVLFDOO\QDQR
Figure 6 Scheme of nanostructured device production.
Notes: Nanostructured systems can be produced using techniques that intrinsically lead to nanoparticles (silver nanoparticles, liposomes) or evolve from other techniques. 
Interfacial deposition and nanoprecipitation have evolved from synthetic polyester manufacturing techniques, and solid lipid nanoparticles are derived from liposome 
production technique. eventually, new techniques are continuously developed: electrospinning of drug-loaded matrix and drug-loaded nanogels. The last class groups different 
production strategies and materials: pH-responsive hydrogels, self-assembling systems, and nanodevices based on natural polymers.
Abbreviation: sol, solution.
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D
2
O, SUVs were obtained by freeze-drying the suspension.78,79 
Alternatively, SUVs could be obtained by homogenization80 
or extrusion81,82 of an organic suspension of LMVs (Figure 7). 
Different phospholipids alone or mixed have been used in 
different works: egg phosphatidylcholine;78,81 soy phos-
phocholine and cholesterol;79,80 egg phosphatidylcholine, 
cholesterol, and α-tocopherol;82,83 and hydrogenated soy 
phosphatidylcholine and cholesterol.77
In general, drug loading can be done by simply adding 
the drug to a solution containing the phospholipids,83,84 or 
after an extrusion process81,82 through an ammonium sulfate 
gradient.77,79,80 The latter realizes remote loading of the drug 
in preformed LMVs produced in presence of (NH
4
)
2
SO
4
. 
(NH
4
)
2
SO
4 
present in the extraliposomal medium is removed 
by dialysis against normal saline. In this way, an ammonium 
sulfate gradient is formed over the liposomal membrane. 
Bupivacaine was loaded by incubating the liposomal formula-
tions with a concentrated bupivacaine solution at the pH range 
5.0–5.5. Remote loading was found to be a more effective 
encapsulation method, since it led to 24–48 hours release in 
saline solution in vitro77,80 and 45 hours in vivo lasting of the 
anesthetic effect,80 which is six to eight times more than the 
release duration obtained with other loading techniques.
Ultimate evolutions in liposome technology involve 
the addition of sugars in their composition, which leads to 
lipid–protein–sugar particles (LPSPs),55,85,86 with the aim of 
accelerating particle degradation in the biological environ-
ment. In one study, also dexamethasone was added to the 
composition to prolong in vivo drug effectiveness.86 In this 
work, LPSPs were prepared through spray-drying: then 
di-palmitoylphosphatidylcholine and bupivacaine were 
dissolved in a given amount of ethanol; sugar (lactose) and 
albumin were dissolved in water and the solutions were 
mixed immediately prior to spray-drying. LPSPs provided 
significantly shorter tissue reaction to foreign body than 
conventional PLA and PLGA microparticles.55
In one of the latest works, liposomes were coated with 
chitosan and alginate to overcome the major drawback asso-
ciated with liposomes: their short shelf-life.77 The coating 
process succeeded in prolonging liposome conservation, 
avoiding drug leakage when stored up to 2 years.
An alternative injectable nanocarrier to liposomes87–89 is 
represented by solid lipid nanoparticles (SLNs), a nanosized 
colloidal system. SLNs have the advantage of a production 
process that avoids the use of organic solvents, namely high-
pressure homogenization. This process can be performed 
either at high or low temperatures. In the first case, the process 
is called hot homogenization:87–89 the drugs (tetracaine87,88 
or bupivacaine89) are dissolved in the melted lipid, and the 
drug-loaded lipid is dispersed in a hot aqueous surfactant 
([WUXVLRQ
,PSODQWHG
,PSODQWHG
6LQJOHXQLODPHOODUYHVLFOHV
0XOWLODPHOODUYHVLFOHV
3KRVSKROLSLGLFILOP
3KRVSKROLSLGLFILOPLQDTXHRXVPHGLXP
+RPRJHQL]DWLRQ )UHH]HGU\LQJ 6SUD\GU\LQJ
/RDGLQJWRLQLWLDOOLSRVRPDOFRPSRVLWLRQ 5HPRWHORDGLQJ
/RDGLQJGXULQJH[WUXVLRQ
0L[LQJ
7KHUDSHXWLFDJHQW
Figure 7 Production process of liposomes.
Notes: Multiple lamellar vesicles (MLVs) can be produced and ready for implant after a suspension of lipophilic film in aqueous solution. In an alternative method, starting 
from MLvs, single lamellar vesicles can be obtained through extrusion, homogenization, freeze-drying, and spray-drying. The therapeutic agent can be incorporated directly 
in the starting phospholipidic film, during the extrusion process, or when the suspension obtained (labeled as remote loading).
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solution to form a pre-emulsion, which is subsequently 
homogenized. The whole process is conducted at 500–1,500 
times the atmospheric pressure. In the second variant, called 
cold homogenization,87 after dissolving the drug in the lipid, 
solidification is done by pouring the drug-loaded lipid in 
liquid nitrogen. This leads to the formation of a solid solution 
(molecular dispersion) of the drug in the lipid matrix. After 
milling the solid solution, the particles are suspended in a 
poloxamer solution, and the resulting suspension is homo-
genized at room temperature and 1,500 times the atmospheric 
pressure. Even though this carrier can be considered safer 
than polymeric nanoparticles, through the avoidance of 
organic toxic solvents, it failed to provide prolonged drug 
release in phosphate–citrate buffer at 37°C (2 hours).87
Nanostructured systems
Nanostructured systems include nanospheres, nanocapsules, 
principally designed as injectable systems, and nanofibers. 
Similar to microstructured systems, synthetic degradable 
polyesters traditionally play an important role in the produc-
tion of nanostructured systems.
Nanospheres have been produced by O/W emulsion90–93 
and nanoprecipitation.94–99 The first technique consists of 
making a solution (oily phase) in which the polymer and the 
drug are dissolved in organic solvents (typically methylene 
chloride or chloroform). The organic solution is subsequently 
poured into an aqueous solution (which often contains PVA, 
which acts as the emulsifier) and the suspension is vortexed. 
The organic solvent can be eliminated at atmospheric pressure 
or by rotary evaporation followed by freeze-drying.34 On the 
other hand, nanoprecipitation consists in dissolving the drug 
in an organic polymer solution, which is added dropwise to 
an aqueous phase. The suspension is magnetically stirred 
until complete solvent evaporation is achieved.
Interfacial deposition (also known as solvent displace-
ment) is an innovative method to produce polyester nano-
capsules with hollow oily nuclei.100–102 This method consists 
in creating an organic phase composed of the drug (benzo-
caine in all reported works), the polymer, acetone, oil, and 
the emulsifier. The organic phase is mixed under magnetic 
stirring with an aqueous solution containing an emulsifier in 
turn, and acetone is evaporated by rotary evaporation. This 
technique can be considered an evolution of the O/W sus-
pension, as interfacial deposition differs from it for solvent 
evaporation from the suspension while mixing it. In vivo 
duration of nerve blockage could reach 4–5 hours.
An advanced nanostructured device for LA delivery 
is represented by electrospun bupivacaine-loaded PLGA 
suture.103 Sutures were produced by adding the drug to the 
polymeric solution used for the electrospinning process. 
They released their entire drug payload in PBS at 37°C in 
12 days and maintained ~12% of their initial tensile strength 
after 14 days in vitro.
Silver nanoparticle suspension and LA solutions (pro-
caine, dibucaine, tetracaine) were prepared to study the 
silver–anesthetic interaction:104 this study, however, is in a 
preliminary phase and far from any clinical application.
Nanogels
The most advanced research on nanostructured drug delivery 
devices focuses on nanogels.
Tan et al105,106 have produced pH-responsive nanogels 
by emulsion polymerization of methacrylic acid–ethyl acry-
late cross-linked with di-allyl phthalate. In a more recent 
study, the same research group succeeded in coating the 
pH-responsive gels using a layer-by-layer technique. In 
this case, layers of poly(allylamine hydrochloride) and 
poly(sodium 4-styrenesulfonate) polyelectrolytes were alter-
nated on the particle surface with the aim of tailoring drug 
release.107 Interestingly, it was found that beyond a certain 
thickness of the coating, the drug release had a slow and 
continuous profile.107 The emulsion polymerization technique 
is used also to produce functionalized thermoresponsive 
nanogels based on (PNIPAM). Thanks to the acrylic acid 
functionalization, the nanogel binds firmly to a cationic drug 
such as bupivacaine.108,109
A smart production process of nanogels is the self-
assembly technique. Self-assembled structures made of 
bupivacaine and liquid crystalline phases (monoglyceride and 
medium-chain triglycerides) have been studied.110 Precisely, 
bupivacaine with appropriate concentrations was mixed 
with glycerol monooleate or binary glycerol monooleate/
medium-chain triglycerides combination, and the mixture 
was heated at 40°C−50°C. The obtained isotropic solutions 
were hydrated by adding PBS and then homogenized by 
vigorous vortexing. The lipid composition led to different 
crystalline nanostructures, which were shown to influence 
the drug release, lasting for up to 48 hours.
Also natural polymers such as alginate-based nanogels 
were investigated for nanogel production111 (Figure 8). 
Alginate/chitosan nanogels loaded with bupivacaine were 
produced starting from a dilute (0.0067% w/v) solution of 
sodium alginate (containing the drug) to which CaCl
2
 was 
added under mechanical stirring. To this solution, a dilute 
chitosan solution was added at a controlled flow rate. The 
second hydrogel consisted of alginate/anionic surfactant 
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(AOT) nanogels, which were produced starting from an 
AOT solution in methylene chloride, which was added to 
an aqueous alginate solution containing bupivacaine, and 
homogenized. PVA solution was eventually added to the 
initial solution, creating a double emulsion, to which calcium 
chloride solution was added to ensure alginate cross-linking. 
Both compositions showed good stability and cytocompat-
ibility. However, alginate/chitosan nanogels showed a slower 
drug release in PBS (pH 7.4) than alginate/AOT surfactant 
(13 hours vs 8 hours).
Concluding remarks and future 
outlook
LAs are powerful drugs whose use can positively affect 
modern medical procedures. Together with their utility, they 
also suffer from safety issues, as most of them show differ-
ent levels of neurotoxicity and cardiotoxicity. Among the 
strategies to overcome this drawback, it is possible to develop 
implantable devices capable of tailored drug release.
The most varied and studied delivery systems are 
microstructured PLA or PLGA microparticles. The many 
manufacturing processes available up to now provide full 
control of the particle size and dispersion, surface topology, 
and structure (particle or capsule). Most of the reviewed 
systems show great stability and prolonged drug release. 
Various strategies have also been developed to avoid initial 
burst release, which can worsen safety issues. Despite 
the maturity of the techniques and release systems, their 
application potential remains to be demonstrated in reality. 
Although synthetic polyesters are often chosen for these 
aims, they show great stability in human body, which is not 
always required in this specific application and could lead to 
non-negligible foreign body response, in addition to acidic 
degradation products. Moreover, an acidic environment 
is not ideal for LA’s effectiveness, as it could shorten the 
drug’s half-life. Liposomes and SLNs do not release acids 
during degradation and can be produced without the use 
of organic solvents. These materials also have drawbacks, 
which are now being addressed, as the particles may be too 
stable in the biological environment but show poor stability 
on the shelf.
Scaling down to the nanoscale brings indeed several 
advantages with a device scale comparable to that of the 
nanostructured biological environment. The strategy to adapt 
techniques and materials developed for microstructures to 
produce nanostructures is not straightforward. Production of 
nanostructured systems could present some peculiar issues, 
mainly due to the high surface-to-volume ratio, which often 
leads to burst release of the drug. To this aim, strategies 
involving specific binding between the drug and the material 
$OJLQDWHGUXJVXUIDFWDQW
$OJLQDWHGUXJFURVVOLQNHU
&KLWRVDQ→FRQWUROOHGIORZUDWH&D&,FURVVOLQNHU
39$&D&,
$OJLQDWHGUXJ
$OJLQDWHGUXJ
$QLRQLFVXUIDFWDQW
5HVXOW
5HVXOW,,VWHS
,VWHS
,VWHS
+RPRJHQL]DWLRQ
Figure 8 Production of hydrogel nanospheres, based on natural polymers.
Notes: To an aqueous solution of alginate and drug, a cross-linker or an anionic surfactant can be added. In the first case, chitosan is added at a controlled flow rate to the 
solution; in the second one it is added to it polyvinyl alcohol (PvA) and a cross-linker. In both cases, the result is an interpenetrated hydrogel structure embedding the local 
anesthetic.
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and a multiscale approach are likely to be the key to reach a 
tailored, prolonged drug release. According to the progress 
in the field, the most promising approaches involve the pres-
ence of nanosystems in micro or macrodevices, to take full 
advantage of the different characteristics brought in a unique 
multiscale device.
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